Home >> Research Area >>Neuroscience>>Muscarinic Receptor>> Umeclidinium bromide

Umeclidinium bromide

MAChR antagonist CAS# 869113-09-7

Umeclidinium bromide

Catalog No. BCC2022----Order now to get a substantial discount!

Product Name & Size Price Stock
Umeclidinium bromide:5mg $216.00 In stock
Umeclidinium bromide:10mg $367.00 In stock
Umeclidinium bromide:25mg $864.00 In stock
Umeclidinium bromide:50mg $1512.00 In stock
Related Products
  • StemRegenin 1 (SR1)

    Catalog No.:BCC3637
    CAS No.:1227633-49-9
  • SU5416

    Catalog No.:BCC1974
    CAS No.:204005-46-9
  • L-Kynurenine

    Catalog No.:BCC3899
    CAS No.:2922-83-0
  • CH 223191

    Catalog No.:BCC3896
    CAS No.:301326-22-7
  • ITE

    Catalog No.:BCC3902
    CAS No.:448906-42-1

Quality Control of Umeclidinium bromide

Number of papers citing our products

Chemical structure

Umeclidinium bromide

3D structure

Chemical Properties of Umeclidinium bromide

Cas No. 869113-09-7 SDF Download SDF
PubChem ID 11519069 Appearance Powder
Formula C29H34BrNO2 M.Wt 508.49
Type of Compound N/A Storage Desiccate at -20°C
Synonyms GSK573719A
Solubility DMSO : ≥ 34 mg/mL (66.86 mM)
*"≥" means soluble, but saturation unknown.
Chemical Name diphenyl-[1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-4-yl]methanol;bromide
SMILES C1C[N+]2(CCC1(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)CCOCC5=CC=CC=C5.[Br-]
Standard InChIKey PEJHHXHHNGORMP-UHFFFAOYSA-M
Standard InChI InChI=1S/C29H34NO2.BrH/c31-29(26-12-6-2-7-13-26,27-14-8-3-9-15-27)28-16-19-30(20-17-28,21-18-28)22-23-32-24-25-10-4-1-5-11-25;/h1-15,31H,16-24H2;1H/q+1;/p-1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of Umeclidinium bromide

DescriptionUmeclidinium bromide is a novel mAChR antagonist. The affinity (Ki) of Umeclidinium bromide for the cloned human M1-M5 mAChRs ranges from 0.05 to 0.16 nM.In Vitro:In human embryonic kidney 293 cells, Umeclidinium bromide (GSK573719A) inhibits the human ether-a-go-go-related gene channel tail current in a concentration-dependent manner (IC50=9.4 μM)[1]. Umeclidinium bromide, previously known as GSK573719, is a novel high-affinity specific mAChR antagonist. It is a potent agent that demonstrates slow functional reversibility at cloned human M3 mAChRs and at endogenous mAChR in isolated human bronchus[2].In Vivo:When Umeclidinium bromide (GSK573719A) is given once daily to mice for 5 consecutive days (0.025 μg intranasally), the level of inhibition on the fifth day is modestly increased above that obtained after a single administration to the same mice (60 versus 35%, respectively). After the fifth day of dosing, the mice are rested for 5 additional days, allowing bronchomotor tone to return to baseline levels. On the sixth day, the mice receive one last dose of antagonist and are once again challenged with Mch. The level of inhibition is essentially the same as that found on the first day of testing, indicating that tolerance is not evident with repeated intranasal delivery of Umeclidinium bromide. By contrast, when Umeclidinium bromide is given orally (2.0 mg/kg) to mice at a dose 100 times the ED50 value (intranasal), there is no observable protection against an Mch challenge[1].

References:
[1]. Salmon M, et al. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013 May;345(2):260-70. [2]. Cazzola M, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012 Jul;64(3):450-504. [3]. Calzetta L, et al. Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi. Eur J Pharmacol. 2017 Jul 14. pii: S0014-2999(17)30470-3.

Protocol

Kinase Assay [1]
Ligand binding assays with Umeclidinium bromide (GSK573719A) and [3H]-N-methyl scopolamine (0.5 nM) are performed using a scintillation proximity assay for M1, M2, and M3 mAChRs and a filtration assay for M4 and M5 mAChRs. For the scintillation proximity assay assay, membranes are incubated with wheat germ agglutinin beads in 50 mM HEPES buffer, pH 7.4, at 4°C for 30 minutes and then with the radioligand in a 96-well OptiPlate for 2 hours at room temperature in the presence of vehicle (1% DMSO) or GSK573719 (0.01-300 nM). At the end of the incubation, the plates are centrifuged (for 5 minutes at 2000g), and radioactivity is counted. For the filtration assay, membranes (M4 and M5) are similarly incubated in HEPES buffer containing the radioligand for 2 hours at room temperature in the presence of vehicle (1% DMSO) or Umeclidinium bromide (0.03-300 nM). Atropine is used as a reference agent. Reactions are terminated by rapid filtration through GF/C filters (glass microfiber binder free 1.2 μ). Membranes are washed with ice-cold 50 mM HEPES and transferred to scintillation vials. Radioactivity is counted in a Scintillation Counter. Reactions are terminated by rapid filtration. Data are obtained from three independent experiments. Specific binding is determined by subtracting nonspecific binding (using 0.3 μM atropine) from total binding. The inhibition constant (Ki) for Umeclidinium bromide is calculated. Membranes containing M3 mAChRs are also incubated for 2 hours at room temperature with increasing concentrations of [3H]-N-methyl scopolamine (0.08-9.24 nM) in the presence or absence of Umeclidinium bromide (0.2-0.5 nM) in 50 mM HEPES, pH 7.4. Nonspecific binding is determined using 10 μM atropine. The saturation data are converted to a scatchard plot for analysis[1].

Animal Administration [1]
Mice[1] Age-matched male BALB/c mice (23-25 gm) are pretreated intranasally (50 μL per mouse) with vehicle (0.9% saline) or Umeclidinium bromide at intervals (0.25-48 hours) prior to methacholine challenge, and placed into individual plethysmograph chambers. Fresh air is supplied by bias flow pumps to the chambers. After baseline respiratory [enhanced pause (Penh)] values are collected, the mice received methacholine (30 mg/mL or EC80) by aerosol delivery (flow=1.6 mL/min×2 minutes). An average Penh is then calculated for 5 minutes. Penh=[(expiratory time/relaxation time)−1]×(peak expiratory flow/peak inspiratory flow), and relaxation time is the amount of time required for 70% of the tidal volume to expire. In some cases, animals are treated on multiple, consecutive days as described in the figure legends. The data are expressed as the mean±S.E.M. percent inhibition of Penh or (mean Penh value of vehicle treated group-Penh for each drug-treated animal) divided by (mean Penh value of vehicle treated group)×100%. Data are analyzed using commercially available software.

References:
[1]. Salmon M, et al. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013 May;345(2):260-70. [2]. Cazzola M, et al. Pharmacology and therapeutics of bronchodilators. Pharmacol Rev. 2012 Jul;64(3):450-504. [3]. Calzetta L, et al. Pharmacological characterization of the interaction between umeclidinium and vilanterol in human bronchi. Eur J Pharmacol. 2017 Jul 14. pii: S0014-2999(17)30470-3.

Umeclidinium bromide Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

Umeclidinium bromide Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of Umeclidinium bromide

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 1.9666 mL 9.833 mL 19.6661 mL 39.3321 mL 49.1652 mL
5 mM 0.3933 mL 1.9666 mL 3.9332 mL 7.8664 mL 9.833 mL
10 mM 0.1967 mL 0.9833 mL 1.9666 mL 3.9332 mL 4.9165 mL
50 mM 0.0393 mL 0.1967 mL 0.3933 mL 0.7866 mL 0.9833 mL
100 mM 0.0197 mL 0.0983 mL 0.1967 mL 0.3933 mL 0.4917 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on Umeclidinium bromide

Umeclidinium bromide is a potent and long-acting antagonist of muscarinic cholinergic receptor (mAChR) with Ki values of 0.16nM, 0.15nM, 0.06nM, 0.05nM and 0.13nM for M1, M2, M3, M4 and M5, respectively [1].

Umeclidinium bromide is developed for the treatment of chronic obstructive pulmonary disease (COPD). It can help patients of COPD achieve sufficient oxygenation of extrapulmonary tissues through dilating the airways. In the in vitro assay, umeclidinium binds to recombinant human mAChRs with Ki value of 0.16nM, 0.15nM, 0.06nM, 0.05nM and 0.13nM for M1-M5, respectively. Umeclidinium is selective against mAChR over other unrelated receptors or channels such as κ and σ opiod receptors, Na+ channel and dopamine transporter. In CHO cells transfected with human recombinant mAChRs, umeclidinium affects the calcium flux responsed to Ach with pA2 values of 9.6-10.6 for M1-M3. In a murine model, administration of umeclidinium can reverse the bronchoconstriction caused by Ach [1].

References:
[1] Salmon M, Luttmann M A, Foley J J, et al. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. Journal of Pharmacology and Experimental Therapeutics, 2013, 345(2): 260-270.

Featured Products
New Products
 

References on Umeclidinium bromide

Umeclidinium bromide/vilanterol combination in the treatment of chronic obstructive pulmonary disease: a review.[Pubmed:25848294]

Ther Clin Risk Manag. 2015 Mar 25;11:481-7.

Chronic obstructive pulmonary disease (COPD) is a common disease among the elderly that could be prevented by smoking cessation. As it is characterized by airflow limitation that is not fully reversible, bronchodilator therapy is the first choice of treatment. Symptomatic COPD patients with or without risk for future exacerbations have a strong indication for the permanent use of long- and ultralong-acting beta2-agonists and/or long-acting muscarinic antagonists. Combining bronchodilators is an effective approach, as they demonstrate synergic action at a cellular level and have additive clinical benefits and fewer adverse events compared with increased doses of the monocomponents. Novel fixed-dose combinations of long-acting beta2-agonists/long-acting muscarinic antagonists in one inhaler have been approved for clinical use by the US Food and Drug Administration and the European Medicines Agency. This review focuses on published clinical trials about the fixed-dose combination of umeclidinium/vilanterol trifenatate in patients with COPD. Results from six studies (five of them of 12 weeks' duration and one that lasted 1 year, including more than 6,000 patients in total) showed that umeclidinium/vilanterol trifenatate improved lung function, dyspnea, and health-related quality of life and decreased the exacerbation rate with no serious adverse events. More longstanding trials are needed to evaluate the effect of the drug on disease progression and compare it directly with other fixed-dose combinations.

Umeclidinium bromide + vilanterol for the treatment of chronic obstructive pulmonary disease.[Pubmed:25382021]

Expert Rev Clin Pharmacol. 2015 Jan;8(1):35-41.

A solid scientific rationale and an increasing body of clinical evidence fully support the use of an antimuscarinic agent combined with a beta-agonist in chronic obstructive pulmonary disease. In this article, we focus on the development of an inhaled fixed dose combination (FDC) of two 24-h bronchodilators, Umeclidinium bromide and vilanterol (UMEC/VI) (ANORO). Several pivotal clinical trials have documented the impact of this combination on lung function and other outcome measures such as quality of life, dyspnea, rescue medication use and exercise capacity, with no clinically meaningful treatment-related changes in vital signs or clinical laboratory parameters. These results allow us to predict that UMEC/VI will have a role in the maintenance treatment of chronic obstructive pulmonary disease. It remains to determine its impact on exacerbations. In any case, trials comparing UMEC/VI with other dual bronchodilator FDCs, and also with inhaled corticosteroid/long-acting beta-agonist FDCs, are needed to assess the advantages, if any, of UMEC/VI FDC over other therapies.

Description

Umeclidinium bromide is a novel mAChR antagonist. The affinity (Ki) of Umeclidinium bromide for the cloned human M1-M5 mAChRs ranges from 0.05 to 0.16 nM.

Keywords:

Umeclidinium bromide,869113-09-7,GSK573719A,Natural Products,Muscarinic Receptor, buy Umeclidinium bromide , Umeclidinium bromide supplier , purchase Umeclidinium bromide , Umeclidinium bromide cost , Umeclidinium bromide manufacturer , order Umeclidinium bromide , high purity Umeclidinium bromide

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: